Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
Cochrane Reviews, 10/09/09
Caslake R R et al. – Currently, there are several different treatments available for people with newly diagnosed Parkinson's including levodopa which is converted into dopamine in the brain, dopamine agonists which mimic the action of dopamine, and monoamine oxidase B (MAO–B) inhibitors (selegiline or rasagiline) which reduce the breakdown of dopamine in the brain. Each of these types of drugs has theoretical advantages and disadvantages. For example, although a very good treatment, levodopa can cause involuntary movements (dyskinesia), painful cramps (dystonia) and a shortened response to each dose (motor fluctuations) after a while, whilst MAO–B inhibitors and dopamine agonists may reduce the risk of these complications but are not so good at improving the symptoms of Parkinson's...Unfortunately the authors only identified two trials (593 patients) so there was only limited evidence. MAO–B inhibitors are one option for the early treatment of PD although they have weaker symptomatic effects than levodopa and dopamine agonists. They may reduce the rate of motor fluctuations compared with initial levodopa therapy and may have fewer significant adverse effects than the older agonists but data are too few to provide reliable conclusions.
Today in Movement Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Paraplegia Following Image-Guided Transforaminal Lumbar Spine Epidural Steroid Injection: Two Case Reports
Pain Medicine, 10/29/09
Progression of Parkinson's disease in the clinical phase: potential markers
The Lancet Neurology, 11/12/09
A comparison of treatment thresholds in two large Parkinsons disease clinical trial cohorts
Movement Disorders, 11/17/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09
Sponsor
Article Search
Sponsor


See Latest Articles


